Weight-Loss drug may also protect heart arteries
NCT ID NCT07657676
First seen Jun 23, 2026 · Last updated Jun 23, 2026
Summary
This study tests whether mazdutide, a weekly injection that helps with weight loss, can slow the buildup of fatty plaque in the heart arteries of 116 overweight or obese adults with coronary heart disease. Participants will receive either the drug or a placebo for 52 weeks, and doctors will use CT scans to measure changes in plaque and inflammation. The goal is to see if this drug can do more than just help with weight—it might also protect the heart.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, 100037, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mazdutide (a weekly injection that targets gut hormones to help with weight and metabolism)
What this could lead to
If it works, this could point toward a treatment that slows heart disease progression in people who are overweight.
What could go wrong
This is a small, early-phase trial with only 116 participants, so results may not apply widely. The drug may not reduce plaque or could cause side effects like nausea or injection-site reactions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.